

G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=&gt; s l11

SAMPLE SEARCH INITIATED 13:49:52 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2389 TO ITERATE

83.7% PROCESSED 2000 ITERATIONS

9 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 44849 TO 50711

PROJECTED ANSWERS: 19 TO 411

L12 9 SEA SSS SAM L11

=&gt; s l11 full

FULL SEARCH INITIATED 13:49:58 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 48075 TO ITERATE

100.0% PROCESSED 48075 ITERATIONS

152 ANSWERS

SEARCH TIME: 00.00.01

L13 152 SEA SSS FUL L11

=&gt; fil hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

170.46

561.65

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-6.75

FILE 'HCAPLUS' ENTERED AT 13:50:04 ON 06 APR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Apr 2006 VOL 144 ISS 15  
FILE LAST UPDATED: 4 Apr 2006 (20060404/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.


This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 113

L14            5 L13

=> d ed abs ibib hitstr 1-5

L14 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 ED Entered STN: 03 Mar 2006  
 GI




AB The title compds. I [R = H, alkyl, SO<sub>2</sub>R<sub>1</sub>, SO<sub>2</sub>NR<sub>1</sub>R<sub>2</sub> or COR<sub>1</sub>; R<sub>1</sub>, R<sub>2</sub> = alkyl; Ring A = Ph or pyridinyl; or pharmaceutically acceptable derivs. thereof] which may be useful in the treatment of anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhea (primary and secondary), endometriosis, emesis (including motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis), mittlemerchz, preeclampsia, premature ejaculation, premature (preterm) labor and Raynaud's disease, were prepared. E.g., a multi-step synthesis of II, starting from tert-Bu 4-iodopiperidine-1-carboxylate and 2-bromopyridine, was given. All the exemplified compds. I showed a K<sub>i</sub> of < 30 nM when tested in screen 1.0 (VIA filter binding assay). The pharmaceutical composition comprising the compds. I is disclosed.


ACCESSION NUMBER: 2006:193685 HCAPLUS  
 DOCUMENT NUMBER: 144:274312  
 TITLE: Preparation of triazolobenzodiazepines as vasopressin antagonists  
 INVENTOR(S): Johnson, Patrick Stephen  
 PATENT ASSIGNER(S): Pfizer Limited, UK; Pfizer Inc.  
 SOURCE: PCT Int. Appl., 47 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006021882	A1	20060302	WO 2005-182711	20050812
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RV: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,				

L14 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of triazolobenzodiazepines as vasopressin antagonists)  
 RN 877678-61-0 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-methyl-1-[4-(2-pyridinyl)-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 877678-62-1 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(methylsulfonyl)-1-[4-(2-pyridinyl)-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 877678-63-2 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-methyl-1-[4-(phenyl-1-piperidinyl)- (9CI) (CA INDEX NAME)

L14 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 PRIORITY APPLN. INFO.: GB 2004-18980 A 20040825  
 US 2004-616601P P 20041005  
 IT 877678-60-9P 877678-64-3P  
 RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of triazolobenzodiazepines as vasopressin antagonists)  
 RN 877678-60-9 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[4-(2-pyridinyl)-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 877678-64-3 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-(4-phenyl-1-piperidinyl)- (9CI) (CA INDEX NAME)




IT 877678-61-0P 877678-62-1P 877678-63-2P  
 877678-65-4P 877678-66-5P 877678-67-6P

L14 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 877678-65-4 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(methylsulfonyl)-1-[4-(phenyl-1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 877678-66-5 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 5-acetyl-8-chloro-5,6-dihydro-1-(4-phenyl-1-piperidinyl)- (9CI) (CA INDEX NAME)

L14 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 877678-67-6 HCAPLUS  
 CN 4H-(1,2,4)Triazolo[4,3-a][1,4]benzodiazepine-5(6H)-sulfonamide,  
 8-chloro-N,N-dimethyl-1-(4-phenyl-1-piperidinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 09 May 2005

AB The invention describes the use of a combination of (A) a vasopressin receptor family antagonist, or a pharmaceutically acceptable derivative thereof; and (B) a COX inhibitor, or a pharmaceutically acceptable derivative thereof, for the treatment or prophylaxis of dysmenorrhea. Preparation of celecoxib is also described.

ACCESSION NUMBER: 2005:395085 HCAPLUS  
 DOCUMENT NUMBER: 142:423900  
 TITLE: Combinations of cyclooxygenase (COX) inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhea


INVENTOR(S): Barker, Laura Daisy; Russell, Rachel Jane; Van der Graaf, Pieter Hadevijn; Wayman, Christopher Peter  
 PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.  
 SOURCE: PCT Int. Appl., 65 pp.  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005039565	A1	20050506	WO 2004-183386	20041014
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, HR, IL, IN, KE, MG, MN, MW, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW				

PRIORITY APPLN. INFO.: GB 2003-25021 A 20031027  
 IT 748804-39-5  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (cyclooxygenase inhibitor-vasopressin receptor antagonist combination for treatment of dysmenorrhea)  
 RN 748804-39-5 HCAPLUS  
 CN 4H-(1,2,4)Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-methyl-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L14 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 17 Dec 2004


AB Use of a phosphodiesterase inhibitor and a vasopressin antagonist in the manufacture of a medicament for the treatment of dysmenorrhea is claimed. Thus, a solution of 4-chloro-2-[[[5-(3,4,5,6-tetrahydro-2H-[1,2']bipyridin-4-yl)-[1,3,4]oxadiazol-2-ylmethyl]amino]methyl]phenylamine (preparation given) was heated with toluene-4-sulfonic acid at 140° for 18 h to give cyclization product, which in CH2Cl2 was treated with aqueous H2CO and then with Na(AcO)3BH to give 8-chloro-5-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridin-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene trihydrochloride. A synergistic effect of a PDE5 inhibitor and a VIA antagonist on AVP induced and basal contractile tone in human myometrium was demonstrated.

ACCESSION NUMBER: 2004:1080801 HCAPLUS  
 DOCUMENT NUMBER: 142:56371  
 TITLE: Therapeutic combinations comprising phosphodiesterase inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhea  
 INVENTOR(S): Bictash, Magda Nabil; Russell, Rachel Jane; Van der Graaf, Pieter Hadevijn; Wayman, Christopher Peter  
 PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.  
 SOURCE: PCT Int. Appl., 53 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004108138	A1	20041216	WO 2004-181848	20040601
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, HR, IL, IN, KE, MG, MN, MW, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW				
CA 2528978	AA	20041216	CA 2004-2528975	20040601
US 2005049255	A1	20050303	US 2004-865194	20040610
PRIORITY APPLN. INFO.: GB 2003-13363 A 20030610 US 2003-484266P P 20030630 WO 2004-181848 W 20040601				

IT 748804-63-99  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (therapeutic combinations comprising phosphodiesterase inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhea)  
 RN 748804-63-9 HCAPLUS  
 CN 4H-(1,2,4)Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L14 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 748806-39-5  
 RI: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (therapeutic combinations comprising phosphodiesterase inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhea)  
 RN 748806-39-5 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-methyl-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



IT 748804-64-0P  
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (vasopressin receptor antagonist; therapeutic combinations comprising phosphodiesterase inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhea)  
 RN 748804-64-0 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ED Entered STN: 02 Sep 2004  
 GI


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [wherein V = -(CH<sub>2</sub>)<sub>2</sub>d(O)e-, -CO-, -CH(alkyl)-; W = O, S(=O)<sub>2</sub>, NH and derivs.; X, Y = independently H, alkyl, halo, OH, CF<sub>3</sub>, OCF<sub>3</sub>, alkoxy, Z = -(CH<sub>2</sub>)<sub>2</sub>f(O)g-, -CO-, -CH(alkyl)-; A = 4-7 membered (un)substituted saturated N-containing heterocycle; B = Ph, (un)substituted saturated N-containing heterocycle; a = 0-2; e, g = 0-1; d, f = 1-2; and their pharmaceutically acceptable derivs.] were prepared as vasopressin receptor VIa antagonists for the treatment of dysmenorrhea. Thus, amination of chloride II (preparation given) with 2-aminomethyl-4-chlorophenylamine (preparation given), cyclization of the aminoimidazole, and reaction of amine with dimethylsulphamoyl chloride gave the triazole III. III displayed a K<sub>i</sub> = 0.24 nM in a VIa filter binding assay.  
 ACCESSION NUMBER: 2004:718543 HCAPLUS  
 DOCUMENT NUMBER: 141:225517  
 TITLE: Preparation of triazoles as vasopressin receptor VIa antagonists for treating of dysmenorrhea  
 INVENTOR(S): Brykows, Justin Stephen; Johnson, Patrick Stephen; Ryckman, Thomas; Storch, Alan  
 PATENT ASSIGNER(S): Pfizer Limited, UK; Pfizer Inc.  
 SOURCE: PCT Int. Appl., 164 pp.  
 CODEN: PIXX22  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004074291	A1	20040902	WO 2004-1B432	20040209
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NL, NO, NZ, OM, OS, PA, PE, PG, PH, PK, PL, PT, RW, SA, SE, SG, SI, SK, SL, SM, SN, SR, ST, SV, SZ, TD, TH, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VE, VU, WO, XA, XB, XN, XZ, YU, ZA, ZW, ZY, ZV, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, BF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004213242	A1	20040902	AU 2004-213242	20040209
CA 2516557	AA	20040902	CA 2004-2516557	20040209
EP 1597260	A1	20051123	EP 2004-709303	20040209
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, NO, MK, CY, BG, HU, SK, CZ, PL, TR, DE, EE, HU, SK				
US 2004186091	A1	20040923	US 2004-782285	20040218
NL 1025527	A1	20040823	NL 2004-100562	20040219
NL 1025527	C2	20050314		
US 2005026810	A1	20050203	US 2004-895630	20040720
NO 200504053	A	20051031	NO 2005-4053	20050831
PRIORITY APPL. INFO.:			GB 2003-3852	A 20030219
			GB 2003-17227	A 20030723
			US 2003-455455P	P 20030318
			US 2003-493823P	P 20030808
			WO 2004-1B432	W 20040209

OTHER SOURCE(S): MARPAT 141:225517

L14 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 methyl-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


IT 748805-32-5P 748805-33-6P  
 RI: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (Via antagonist; preparation of triazoles as vasopressin receptor VIa antagonists for treating of dysmenorrhea)  
 RN 748805-32-5 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(4-methyl-2-morpholinyl)methyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-, (-) (9CI) (CA INDEX NAME)

Rotation (-).



RN 748805-33-6 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(4-methyl-2-morpholinyl)methyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-, (+) (9CI) (CA INDEX NAME)


Rotation (+).



IT 748804-60-6P, 1-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748804-63-9P  
 748804-71-9P, 8-Chloro-1-[1-(pyrimidin-2-yl)pyrrolidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748804-79-9P  
 4-(8-Chloro-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulen-1-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-6'-carbonitrile 748804-98-0P  
 2-Chloro-1-[8-chloro-1-[3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl]-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]ethanone 748805-02-9P


method

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 748805-09-6P, 8-Chloro-5-[(pyrrolidin-2-yl)methyl]-1-[3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-13-2P 748805-14-3P, 5-(Azetidin-3-yl)-8-chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-15-4P, 8-Chloro-5-(pyrrolidin-3-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-20-1P 748805-46-5P, 8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-thia-2,3,10b-triazabenz[e]azulene 748806-39-3P, 8-Chloro-5-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (Via receptor antagonists; prepn. of triazoles as vasopressin receptor  
 Via antagonists for treating of dysmenorrhea)  
 RN 748804-60-6 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-63-9 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 748804-71-9 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-79-7 HCAPLUS  
 CN 2-Pyridinecarbonitrile, 6-[4-(8-chloro-4H,6H-[1,2,4]triazolo[4,3-a][4,1]benzodiazepin-1-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 748804-98-0 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-(chloroacetyl)-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 748805-02-9 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-5-[(2S)-2-pyrrolidinylcarbonyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● 3 HCl

RN 748805-09-6 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-5-[(2S)-2-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 748805-13-2 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(2-morpholinylmethyl)-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 748805-14-3 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 5-(3-azetidinyl)-8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 748805-15-4 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-5-(3-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 748805-20-1 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine-5(6H)-carboxamide, 8-chloro-N,N-dimethyl-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 748805-66-5 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 748806-39-5 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-methyl-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 748804-61-7P, 5-Methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene  
 748804-62-8P, 1-[1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]ethanone 748804-64-0P, 8-Chloro-5-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene trihydrochloride 748804-65-1P, 8-Chloro-5-isopropyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene trihydrochloride 748804-66-2P, 8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5-(tetrahydropyran-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748804-67-3P, 1-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]ethanone dihydrochloride 748804-68-4P, [8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]cyclopropylmethanone dihydrochloride 748804-69-5P, 1-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]-2,2-dimethylpropan-1-one dihydrochloride 748804-70-8P, 8-Chloro-5-methanesulfonyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748804-72-0P, 8-Chloro-5-methyl-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748804-73-1P, 8-Chloro-5-isopropyl-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748804-74-2P, 8-Chloro-5-methanesulfonyl-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748804-75-3P, [8-Chloro-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]cyclopropylmethanone 748804-76-4P, 1-[8-Chloro-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]-2,2-dimethylpropan-1-one 748804-77-5P, 1-[8-Chloro-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]ethanone 748804-78-6P, 8-Chloro-1-(6'-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene 748804-80-0P, 4-(8-Chloro-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulen-1-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-6'-carboxylic acid amide 748804-81-1P, 13-Chloro-3-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-2,4,5,8-tetraazatricyclo[9.4.0.0,2,6]pentadeca-1(11),3,5,12,14-pentane 748804-82-2P, 1-(13-Chloro-3-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-2,4,5,8-tetraazatricyclo[9.4.0.0,2,6]pentadeca-1(11),3,5,12,14-pentane-8-yl)ethanone 748804-83-3P,


L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)  
 13-Chloro-8-methyl-3-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-2,4,5,8-tetraazatricyclo[9.4.0.02,6]pentadeca-1(11),3,5,12,14-pentaene  
 748804-84-4P, 3-[1-(Pyrimidin-2-yl)piperidin-4-yl]-8-oxa-2,4,5-triazatricyclo[9.4.0.02,6]pentadeca-1(11),3,5,12,14-pentaene  
 748804-85-5P, 8-Chloro-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene 748804-86-6P,  
 13-Chloro-3-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-8-oxa-2,4,5-triazatricyclo[9.4.0.02,6]pentadeca-1(11),3,5,12,14-pentaene  
 748804-87-7P, 3-(1,2,3,4,5,6-Hexahydro-[1,2']bipyridinyl-4-yl)-8-oxa-2,4,5-triazatricyclo[9.4.0.02,6]pentadeca-1(11),3,5,12,14-pentaene dihydrochloride 748804-88-8P, 8-Chloro-1-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene 748804-89-9P, 7-Chloro-1-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene dihydrochloride 748804-90-2P, 1-(1,2,3,4,5,6-Hexahydro-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene 748804-91-3P,  
 8-Methoxy-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene dihydrochloride 748804-92-4P,  
 8-Fluoro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene 748804-93-5P, 8,9-Difluoro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene dihydrochloride 748804-94-6P,  
 9-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene dihydrochloride 748804-95-7P,  
 1-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-8-trifluoromethoxy-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene 748804-96-8P,  
 8-Methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene 748804-99-1P, 2-(Azetidin-1-yl)-1-[8-chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]ethanone 748805-00-7P,  
 1-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]-2-(pyrrolidin-1-yl)ethanone 748805-01-8P, [8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]pyrrolidin-3-ylmethanone trihydrochloride 748805-03-0P 748805-04-1P  
 748805-05-2P 748805-06-3P 748805-07-4P  
 748805-08-5P 748805-10-5P 748805-11-0P  
 748805-12-1P 748805-16-5P, 8-Chloro-5-(piperidin-4-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene trihydrochloride 748805-17-6P,  
 8-Chloro-5-[1,4]oxazepan-6-yl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene trihydrochloride 748805-18-7P, [8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]morpholin-4-ylmethanone 748805-19-8P 748805-21-2P 748805-22-3P  
 748805-23-4P, [2-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]ethyl]dimethylamine trihydrochloride 748805-24-5P,  
 8-Chloro-5-[2-(pyrrolidin-1-yl)ethyl]-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene trihydrochloride 748805-25-6P, [8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]acetic acid methyl ester 748805-26-7P, 1-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]-3-methoxypropan-1-one 748805-27-8P  
 748805-28-9P, 8-Chloro-5-(1-methylpyrrolidin-2-yl)-2-ylmethyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene trihydrochloride 748805-29-0P

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)  
 748805-30-3P 748805-31-4P 748805-34-7P,  
 [8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]((2S)-1-methylpyrrolidin-2-yl)methanone 748805-35-8P 748805-36-9P 748805-37-0P  
 748805-38-1P 748805-39-2P 748805-40-5P  
 748805-41-6P, [8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl](tetrahydropyran-4-yl)methanone 748805-42-7P, [8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]1-(methyl)piperidin-4-yl)methanone 748805-43-8P,  
 8-Chloro-5-(1-methylazetidin-3-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-44-9P 748805-45-0P 748805-46-1P  
 748805-47-2P 748805-48-3P, 8-Chloro-5-(1-methylpyrrolidin-3-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-49-4P,  
 8-Chloro-5-(1-isopropylpyrrolidin-3-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene trihydrochloride 748805-50-7P, 2-[8-Chloro-1-(1-(pyrimidin-2-yl)piperidin-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]ethanol 748805-51-8P, 8-Chloro-5-(2-methoxyethyl)-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-52-9P, 8-Chloro-5-(pyrimidin-2-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-53-0P, 8-Chloro-5-(pyrimidin-4-yl)-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-54-1P, 8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-carboxaldehyde 748805-55-2P, 8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-sulfonic acid dimethylamide 748805-56-3P, 8-Chloro-5-(pyridin-2-yl)methyl-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-57-4P 748805-58-5P  
 748805-59-6P, 8-Chloro-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-4H,6H-2,3,5,10b-tetraazabenz[e]azulene-5-sulfonic acid dimethylamide 748805-60-7P, 8-Chloro-5-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4,5-dihydro-2,3,5,10b-tetraazabenz[e]azulen-6-one 748805-61-0P, 13-Chloro-9-methyl-3-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-2,4,5,9-tetraazatricyclo[9.4.0.02,6]pentadeca-1(11),3,5,12,14-pentaene 748805-62-1P, 13-Chloro-8-methyl-3-[1-(pyrimidin-2-yl)piperidin-4-yl]-2,4,5,8-tetraazatricyclo[9.4.0.02,6]pentadeca-1(11),3,5,12,14-pentaene 748805-63-2P,  
 8-Chloro-5,6-dimethyl-1-[1-(pyrimidin-2-yl)piperidin-4-yl]-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene 748805-64-3P,  
 1-(3,4,5,6-Tetrahydro-2H-[1,2']bipyridinyl-4-yl)-8-trifluoromethyl-4H,6H-5-oxa-2,3,10b-triazabenz[e]azulene 748805-65-4P,  
 10-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-6,7-dihydro-4H-5,8-dioxo-2,3,12b-triazabenz[e]azulene 748805-67-6P, 8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-thia-2,3,10b-triazabenz[e]azulene 5-oxide 748805-68-7P, 8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-5-thia-2,3,10b-triazabenz[e]azulene 5,5-dioxide  
 R1: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (Via receptor antagonist; prepn. of triazoles as vasopressin receptor  
 Via antagonists for treating of dysmenorrhea)  
 RN 748804-61-7 HCAPLUS

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 5,6-dihydro-5-methyl-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-62-8 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 5-acetyl-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-64-0 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-methyl-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 748804-65-1 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(1-methylethyl)-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)




RN 748804-66-2 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-5-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)



L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 748804-67-3 HCAPLUS  
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 5-acetyl-8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)




RN 748804-68-4 HCAPLUS  
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-(cyclopropylcarbonyl)-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 748804-72-0 HCAPLUS  
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-methyl-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-73-1 HCAPLUS  
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-methylethyl-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 748804-69-5 HCAPLUS  
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-(2,2-dimethyl-1-oxopropyl)-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)




RN 748804-70-8 HCAPLUS  
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(methylsulfonyl)-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 748804-74-2 HCAPLUS  
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(methylsulfonyl)-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-75-3 HCAPLUS  
CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-(cyclopropylcarbonyl)-5,6-dihydro-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 748804-76-4 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-(2,2-dimethyl-1-oxopropyl)-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-77-5 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 5-acetyl-8-chloro-5,6-dihydro-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 748804-81-1 HCAPLUS  
 CN [1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 9-chloro-4,5,6,7-tetrahydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-82-2 HCAPLUS  
 CN [1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 5-acetyl-9-chloro-4,5,6,7-tetrahydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-83-3 HCAPLUS  
 CN [1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 9-chloro-4,5,6,7-tetrahydro-5-methyl-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 748804-78-6 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-1-[1-(6-(trifluoromethyl)-2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-80-0 HCAPLUS  
 CN 2-Pyridinecarboxamide, 6-[4-(8-chloro-4H,6H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)


L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 748804-84-4 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 6,7-dihydro-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-85-5 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-86-6 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 9-chloro-6,7-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 748804-87-7 HCAPLUS  
 CN 4H,6H-[1,2,4]Triazolo[4,3-a][4,1]benzoxazine, 6,7-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 748804-88-8 HCAPLUS  
 CN 4H,6H-[1,2,4]Triazolo[4,3-a][4,1]benzoxazine, 8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-89-9 HCAPLUS  
 CN 4H,6H-[1,2,4]Triazolo[4,3-a][4,1]benzoxazine, 7-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 748804-92-4 HCAPLUS  
 CN 4H,6H-[1,2,4]Triazolo[4,3-a][4,1]benzoxazine, 8-fluoro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-93-5 HCAPLUS  
 CN 4H,6H-[1,2,4]Triazolo[4,3-a][4,1]benzoxazine, 8,9-difluoro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 748804-90-2 HCAPLUS  
 CN 4H,6H-[1,2,4]Triazolo[4,3-a][4,1]benzoxazine, 1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-91-3 HCAPLUS  
 CN 4H,6H-[1,2,4]Triazolo[4,3-a][4,1]benzoxazine, 8-methoxy-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 748804-94-6 HCAPLUS  
 CN 4H,6H-[1,2,4]Triazolo[4,3-a][4,1]benzoxazine, 9-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-95-7 HCAPLUS  
 CN 4H,6H-[1,2,4]Triazolo[4,3-a][4,1]benzoxazine, 1-[1-(2-pyridinyl)-4-piperidinyl]-8-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 748804-96-8 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][4,1]benzodiazepine, 8-methyl-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748804-99-1 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 5-(1-azetidinylacetyl)-8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 748805-00-7 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-5-(1-pyrrolidinylacetyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 748805-01-8 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-5-(3-pyrrolidinylcarbonyl)-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




●3 HCl

RN 748805-03-0 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-5-[(2R)-2-pyrrolidinylcarbonyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



●3 HCl

RN 748805-04-1 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(3-piperidinylcarbonyl)-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A






●3 HCl

RN 748805-05-2 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(2R)-2-piperidinylcarbonyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl


RN 748805-06-3 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(2S)-2-piperidinylcarbonyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●3 HCl

RN 748805-08-5 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(2S)-2-morpholinylcarbonyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)




●3 HCl

RN 748805-10-9 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(2S)-2-piperidinylmethyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




●3 HCl

RN 748805-07-4 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(3-morpholinylcarbonyl)-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)




Absolute stereochemistry.



RN 748805-11-0 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(2R)-2-piperidinylmethyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 748805-12-1 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(3-piperidinylmethyl)-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 748805-16-5 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(4-piperidinyl)-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 748805-17-6 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1,4-oxazepin-6-yl)-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 748805-18-7 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(4-morpholinyl)-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 748805-19-8 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine-5(6H)-carboxylic acid, 8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-, methyl ester (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 748805-21-2 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-5-(1-pyrrolidinyl)-, trihydrochloride (9CI) (CA INDEX NAME)



PAGE 1-A


L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A




RN 748805-22-3 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 748805-23-4 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine-5(6H)-ethanamine, 8-chloro-N,N-dimethyl-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)


L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A




● 3 HCl

RN 748805-25-6 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine-5(6H)-acetic acid, 8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 748805-26-7 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(3-methoxy-1-oxopropyl)-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● 3 HCl

RN 748805-24-5 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-5-[2-(1-pyrrolidinyl)ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 748805-27-8 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-[3-(dimethylamino)-1-oxopropyl]-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 748805-28-9 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(2S)-1-methyl-2-pyrrolidinylmethyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 748805-29-0 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-  
 [(2S)-1-methyl-2-piperidinylmethyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-  
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 748805-30-3 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-  
 [(2R)-1-methyl-2-piperidinylmethyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-  
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 748805-31-4 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(1-  
 methyl-3-piperidinyl)methyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-,  
 trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 748805-34-7 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-  
 [(2S)-1-methyl-2-pyrrolidinylcarbonyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-  
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 748805-35-8 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-  
 [(2R)-1-methyl-2-pyrrolidinylcarbonyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-  
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 748805-36-9 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(1-  
 methyl-3-pyrrolidinyl)methyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI)  
 (CA INDEX NAME)

PAGE 1-A






L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 748805-37-0 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-  
 [[[(2R)-1-methyl-2-piperidinyl]carbonyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-  
 , trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●3 HCl

RN 748805-38-1 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(1-  
 methyl-3-piperidinyl)carbonyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI)  
 (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 748805-39-2 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(4-  
 methyl-2-morpholinyl)carbonyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI)  
 (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 748805-40-5 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(4-  
 methyl-3-morpholinyl)carbonyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI)  
 (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 748805-41-6 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-  
 pyridinyl)-4-piperidinyl]-5-[(tetrahydro-2H-pyran-4-yl)carbonyl]- (9CI)  
 (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 748805-42-7 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(1-methyl-4-piperidinyl)carbonyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 748805-43-8 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(1-methyl-3-azetidiny)l]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 748805-44-9 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(1-methylethyl)-3-azetidiny]l-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 748805-45-0 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(1-methyl-4-piperidinyl)-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 748805-46-1 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-[(1-ethyl-4-piperidinyl)-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

Et

RN 748805-47-2 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[1-(1-methylethyl)-4-piperidinyl]-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

1-Pr

RN 748805-48-3 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(1-methyl-3-pyrrolidinyl)-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

Me

RN 748805-49-4 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[1-(1-methylethyl)-3-pyrrolidinyl]-1-[1-(2-pyridinyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

1-Pr


● 3 HCl

RN 748805-50-7 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine-5(6H)-ethanol, 8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 748805-51-8 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(2-methoxyethyl)-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748805-52-9 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-5-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 748805-53-0 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]-5-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 748805-54-1 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine-5(6H)-carboxaldehyde, 8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 748805-55-2 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine-5(6H)-sulfonamide, 8-chloro-N,N-dimethyl-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 748805-56-3 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-(2-pyridinylmethyl)-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 748805-57-4 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-1-[1-(2-pyrimidinyl)-4-piperidinyl]-5-(2-thiazolylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 748805-58-5 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-[(1H-pyrazol-3-yl)methyl]-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 748805-59-6 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine-5(6H)-sulfonamide, 8-chloro-N,N-dimethyl-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748805-60-9 HCAPLUS  
 CN 6H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepin-6-one, 8-chloro-4,5-dihydro-5-methyl-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748805-61-0 HCAPLUS  
 CN [1,2,4]Triazolo[4,3-a][1,5]benzodiazocine, 9-chloro-4,5,6,7-tetrahydro-6-methyl-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 748805-62-1 HCAPLUS  
 CN [1,2,4]Triazolo[4,3-a][1,4]benzodiazocine, 9-chloro-4,5,6,7-tetrahydro-5-methyl-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748805-63-2 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5,6-dimethyl-1-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748805-64-3 HCAPLUS  
 CN 4H,6H-[1,2,4]Triazolo[4,3-a][4,1]benzodiazepine, 1-[1-(2-pyridinyl)-4-piperidinyl]-8-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 748805-65-4 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[3,4-f][1,4,7]benzodioxazine, 10-chloro-6,7-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 748805-67-6 HCAPLUS  
 CN 4H,6H-[1,2,4]Triazolo[4,3-a][4,1]benzothiazepine, 8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-, 5-oxide (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 748805-68-7 HCAPLUS  
 CN 4H,6H-[1,2,4]Triazolo[4,3-a][4,1]benzothiazepine, 8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-, 5,5-dioxide (9CI) (CA INDEX NAME)




IT 748804-97-9P, 1-[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]-2-dimethylaminoethanone 748806-17-9P 748806-18-0P  
 748806-19-1P 748806-20-4P 748806-21-5P  
 748806-22-6P 748806-23-7P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (intermediate, V1a receptor antagonist; preparation of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)  
 RN 748804-97-9 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5-

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 [(dimethylamino) acetyl]-5,6-dihydro-1-[1-(2-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 748806-17-9 HCAPLUS  
 CN 1-Pyrrolidinecarboxylic acid, 2-[[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]carbonyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 748806-18-0 HCAPLUS  
 CN 1-Pyrrolidinecarboxylic acid, 2-[[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]carbonyl]-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 748806-19-1 HCAPLUS  
 CN 1-Piperidinecarboxylic acid, 3-[[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 748806-20-4 HCAPLUS  
 CN 1-Piperidinecarboxylic acid, 2-[[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]carbonyl]-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 748806-21-5 HCAPLUS  
 CN 1-Piperidinecarboxylic acid, 2-[[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]carbonyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A




RN 748806-23-7 HCAPLUS  
 CN 4-Morpholinecarboxylic acid, 2-[[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




IT 748806-16-0P, tert-Butyl 3-[[8-Chloro-1-(1,2,3,4,5,6-hexahydro-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]carbonyl]pyrrolidine-1-carboxylate 748806-24-0P,  
 3-[[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]azetidine-1-carboxylic acid tert-butyl ester 748806-25-0P, 3-[[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]pyrrolidine-1-carboxylic acid tert-butyl ester 748806-26-0P,

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 748806-22-6 HCAPLUS  
 CN 4-Morpholinecarboxylic acid, 3-[[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A




L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 4-[[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-2,3,5,10b-tetraazabenz[e]azulen-5-yl]piperidine-1-carboxylic acid tert-butyl ester 748806-27-1P, 6-[[8-Chloro-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-4H,6H-10b-2,3,5,10b-tetraazabenz[e]azulen-5-yl]-[1,4]oxazepan-4-carboxylic acid 748806-40-0P,  
 8-Chloro-5-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraazabenz[e]azulene dibesylate  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate, prepn. of triazoles as vasopressin receptor V1a antagonists for treating of dysmenorrhea)

RN 748806-16-8 HCAPLUS  
 CN 1-Pyrrolidinecarboxylic acid, 3-[[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 748806-24-8 HCAPLUS  
 CN 1-Acetidinecarboxylic acid, 3-[[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 748806-25-9 HCAPLUS  
 CN 1-Pyrrolidinecarboxylic acid, 3-[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 748806-26-0 HCAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 748806-27-1 HCAPLUS  
 CN 1,4-Oxazepine-4(5H)-carboxylic acid, 6-[8-chloro-1-[1-(2-pyridinyl)-4-piperidinyl]-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-5(6H)-yl]tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A


RN 748806-40-8 HCAPLUS  
 CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-5,6-dihydro-5-methyl-1-[1-(2-pyridinyl)-4-piperidinyl]-, dibenzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 748806-39-5  
 CMF C21 H23 Cl N6




L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 98-11-3  
CHF C6 H6 O3 S

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RS FORMAT

L14 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN  
ED Entered STN: 12 May 1984  
GI

AB The title compds. I (R = H, Br, Cl, H2N, SH, CF3, HOCH2, etc.; R1 = H, Br, Cl, H2N; R2 = Ph, substituted Ph, 2-pyridyl; R3 = H or Me) were synthesized and evaluated for central nervous system (CNS) activity. In addition to antianxiety activity, some compds. were also active as antidepressants and psychotropics. Selective manipulation of substituents at C-1, C-8, and the ortho position of the C-6 Ph group resulted in compds. with a broad range of activities in the CNS activity screen. Structure-activity relations are discussed.

ACCESSION NUMBER: 1980:212 HCAPLUS

DOCUMENT NUMBER: 92:212

TITLE: 6-Acyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity

AUTHOR(S): Hester, Jackson B., Jr.; Von Voigtlander, Philip

CORPORATE SOURCE: Upjohn Co., Kalamazoo, MI, 49001, USA

SOURCE: Journal of Medicinal Chemistry (1979), 22(11), 1390-8

CODEN: JMCHAM; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 92:212


IT 71368-70-2P

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (Preparation and pharmacol. of)

RN 71368-70-2 HCAPLUS

CN 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-6-phenyl-1-(4-phenyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

L14 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



10782285amended

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

28.08

589.73

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.75

-10.50

STN INTERNATIONAL LOGOFF AT 13:50:51 ON 06 APR 2006